Wordt geladen...
A233 VEDOLIZUMAB FOR STEROID & INFLIXIMAB-REFRACTORY ICI-COLITIS
BACKGROUND: Immune checkpoint inhibitors (ICI), such as anti-PD1, improve survival in melanoma, renal carcinoma and prostate cancer. However, by disinhibiting the immune system, these treatments cause significant immune-related adverse events (irAE), including colitis. For ICI-colitis, guidelines su...
Bewaard in:
| Gepubliceerd in: | J Can Assoc Gastroenterol |
|---|---|
| Hoofdauteurs: | , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Oxford University Press
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7043547/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwz047.232 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|